AR070429A1 - Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa - Google Patents
Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasaInfo
- Publication number
- AR070429A1 AR070429A1 ARP090100560A ARP090100560A AR070429A1 AR 070429 A1 AR070429 A1 AR 070429A1 AR P090100560 A ARP090100560 A AR P090100560A AR P090100560 A ARP090100560 A AR P090100560A AR 070429 A1 AR070429 A1 AR 070429A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- hetero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona derivados heterocíclicos que modulan la actividad de la estearoil-CoA-desaturasa. También se abarcan métodos para utilizar estos derivados con el fin de modular la actividad de la estearoil-CoA-desaturasa, y composiciones farmacéuticas que comprenden tales derivados. Reivindicacion 1: Un compuesto representado por la formula (1): en donde: Q es cualquiera de la formula (2); W es -N(R6)C(O)-, -R8-C(O)N(R6)-, -R8-OC(O)N(R6)-, -N(R6)C(O)O-, -N(R6)C(O)N(R6), -O-, -S-, -N(R6)-, -S(O)t-, -N(R6)S(O)t-, -S(O)tN(R6)-, -OS(O)tN(R6)-, -R8-C(O)-, -OC(O)-, -C(O)O-, -N(R6)C(=N(R6a))N(R6)-, -N(R6)-((R6a)N=)C-, -C(=N(R6a))N(R6)-, o un enlace directo; V es -C(O)N(R6)-, -S(O)t-, -S(O)2N(R6)-, -C(O)-, -R8-C(O)O-, -R8-C(O)N(R6)-, -R8-C(O)-, -C(=N(R6a))N(R6)-, o un enlace directo; t es 1 o 2; R1 es halogeno, hidrogeno, alquilo, alquenilo, alquinilo, alcoxilo, hidroxi-alquilo, alcoxi-alquilo, cicloalquilo, cicloalquil-alquilo, arilo, aralquilo, heterociclilo, heterociclil-alquilo, hetero-arilo, o hetero-aril-alquilo; o R1 es una estructura de multiples anillos que tiene de 2 a 4 anillos, en donde los anillos son independientemente cicloalquilo, heterociclilo, arilo o hetero-arilo, y en donde algunos o todos los anillos pueden estar fusionados unos con otros: R2 es hidrogeno, alquilo, alquenilo, alquinilo, alcoxilo, hidroxi-alquilo, alcoxi-alquilo, cicloalquilo, cicloalquil-alquilo, arilo, halo-alquilo, aralquilo, heterociclilo, heterociclil-alquilo, hetero-arilo o hetero-aril-alquilo; o R2 es una estructura de multiples anillos que tiene de 2 a 4 anillos, en donde los anillos son independientemente cicloalquilo, heterociclilo, arilo o hetero-arilo, y en donde algunos o todos los anillos pueden estar fusionados unos con otros; R3 es hidrogeno o alquilo; R4 y R4a son independientemente hidrogeno, alquilo, halo-alquilo, hidroxilo, hidroxi-alquilo, alcoxilo, cicloalquil-alquilo o aralquilo; o R4 y R4a se toman juntos para formar un grupo oxo (=O), cicloalquilo o heterociclilo; R5 y R5a son independientemente hidrogeno, alquilo o halo-alquilo; o R4 y R4a se toman juntos para formar un cicloalquilo, arilo, hetero-arilo o heterociclilo, y los restantes R4a y R5a son como se describen anteriormente; R6 es independientemente hidrogeno, alquilo, hidroxi-alquilo, cicloalquil-alquilo, arilo, hetero-arilo, heterociclilo o aralquilo; R6a es independientemente hidrogeno, alquilo, cicloalquil-alquilo, o ciano; R7 es hidrogeno, alquilo, trifluoro-metilo, arilo, cicloalquilo, hetero-arilo, heterociclilo, hidroxi-alquilo, cicloalquil-alquilo o aralquilo; y R8 es independientemente un enlace directo, una cadena de alquileno recta o ramificada opcionalmente sustituida, una cadena de alquenileno recta o ramificada opcionalmente sustituida, o una cadena de alquinileno recta o ramificada opcionalmente sustituida; como un estereoisomero, enantiomero, o tautomero de los mismos, una sal farmacéuticamente aceptable de los mismos, o un pro-fármaco del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3013708P | 2008-02-20 | 2008-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070429A1 true AR070429A1 (es) | 2010-04-07 |
Family
ID=40740143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100560A AR070429A1 (es) | 2008-02-20 | 2009-02-18 | Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8049016B2 (es) |
| EP (1) | EP2245029B1 (es) |
| JP (2) | JP5507474B2 (es) |
| KR (1) | KR101584826B1 (es) |
| CN (1) | CN102007123B (es) |
| AR (1) | AR070429A1 (es) |
| AU (1) | AU2009216769A1 (es) |
| BR (1) | BRPI0907826A2 (es) |
| CA (1) | CA2715947C (es) |
| CL (1) | CL2009000381A1 (es) |
| CO (1) | CO6290655A2 (es) |
| CR (1) | CR11629A (es) |
| CU (1) | CU23890B1 (es) |
| EA (1) | EA022797B1 (es) |
| EC (1) | ECSP10010411A (es) |
| HK (1) | HK1144808A1 (es) |
| HN (1) | HN2010001647A (es) |
| IL (1) | IL207578A (es) |
| JO (1) | JO3014B1 (es) |
| MA (1) | MA32150B1 (es) |
| MX (1) | MX2010009158A (es) |
| MY (1) | MY156317A (es) |
| NZ (1) | NZ587350A (es) |
| PE (1) | PE20091473A1 (es) |
| SV (1) | SV2010003650A (es) |
| TW (1) | TWI457338B (es) |
| UA (1) | UA105000C2 (es) |
| WO (1) | WO2009103739A1 (es) |
| ZA (1) | ZA201005725B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090040385A (ko) | 2006-08-15 | 2009-04-23 | 노파르티스 아게 | 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물 |
| EA200900820A1 (ru) * | 2006-12-20 | 2010-02-26 | Новартис Аг | 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд) |
| EA022797B1 (ru) | 2008-02-20 | 2016-03-31 | Новартис Аг | ТРИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ СТЕАРОИЛ-CoA-ДЕСАТУРАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ |
| US8168794B2 (en) | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| PH12012500648A1 (en) * | 2009-10-01 | 2012-11-12 | Novartis Ag | Pyrazole derivatives which modulate stearoyl-coa desaturase |
| US9187472B2 (en) * | 2012-05-11 | 2015-11-17 | Abbvie Inc. | NAMPT inhibitors |
| KR20150013548A (ko) | 2012-05-21 | 2015-02-05 | 노파르티스 아게 | 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드 |
| JP2019529342A (ja) * | 2016-09-08 | 2019-10-17 | 四川科倫博泰生物医薬股▲フン▼有限公司Ｓｉｃｈｕａｎ Ｋｅｌｕｎ−Ｂｉｏｔｅｃｈ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 新型２−アミドチアゾール誘導体、及びその製造方法と用途 |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| CN110392833A (zh) | 2017-01-06 | 2019-10-29 | 优曼尼蒂治疗公司 | 治疗神经病症的方法 |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| SG11202108079RA (en) | 2019-01-24 | 2021-08-30 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| CN114222732B (zh) * | 2019-10-28 | 2023-04-04 | 南京明德新药研发有限公司 | 一种尿酸促排剂及其合成方法和其在医药上的应用 |
| AU2020407664A1 (en) * | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058617A (en) | 1972-10-04 | 1977-11-15 | Ciba-Geigy Corporation | Imidazoles and pharmaceutical composition |
| CH590267A5 (es) * | 1972-10-04 | 1977-07-29 | Ciba Geigy Ag | |
| IL44282A (en) | 1974-02-25 | 1979-01-31 | Ciba Geigy Ag | 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them |
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| CA2381215A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | P38map kinase inhibitors |
| WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| WO2002100433A1 (en) | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| WO2005077937A1 (en) | 2004-01-09 | 2005-08-25 | Cadila Healthcare Limited | Substituted hydroxamic acid derivatives as tnf inhibitors |
| EP1621539A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| US7767677B2 (en) * | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| WO2006034341A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| EP2029138A1 (en) * | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| DE602007010287D1 (de) | 2006-06-05 | 2010-12-16 | Novartis Ag | Organische verbindungen |
| KR20090040385A (ko) | 2006-08-15 | 2009-04-23 | 노파르티스 아게 | 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물 |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| JP5351025B2 (ja) * | 2006-09-22 | 2013-11-27 | ノバルティス アーゲー | ヘテロ環式有機化合物 |
| GB0621452D0 (en) * | 2006-10-27 | 2006-12-06 | Ucl Business Plc | Therapy for liver disease |
| EA200900820A1 (ru) | 2006-12-20 | 2010-02-26 | Новартис Аг | 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд) |
| MX2010008818A (es) * | 2008-02-13 | 2010-09-07 | Eisai R&D Man Co Ltd | Derivado de bicicloamina. |
| EA022797B1 (ru) | 2008-02-20 | 2016-03-31 | Новартис Аг | ТРИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ СТЕАРОИЛ-CoA-ДЕСАТУРАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ |
| EP2307379A2 (en) | 2008-06-27 | 2011-04-13 | Novartis AG | Organic compounds |
-
2009
- 2009-02-18 EA EA201001315A patent/EA022797B1/ru not_active IP Right Cessation
- 2009-02-18 CN CN200980113852.9A patent/CN102007123B/zh not_active Expired - Fee Related
- 2009-02-18 UA UAA201010238A patent/UA105000C2/uk unknown
- 2009-02-18 KR KR1020107020848A patent/KR101584826B1/ko not_active IP Right Cessation
- 2009-02-18 MX MX2010009158A patent/MX2010009158A/es active IP Right Grant
- 2009-02-18 AU AU2009216769A patent/AU2009216769A1/en not_active Abandoned
- 2009-02-18 MY MYPI2010003768A patent/MY156317A/en unknown
- 2009-02-18 JP JP2010547169A patent/JP5507474B2/ja not_active Expired - Fee Related
- 2009-02-18 AR ARP090100560A patent/AR070429A1/es unknown
- 2009-02-18 WO PCT/EP2009/051926 patent/WO2009103739A1/en active Application Filing
- 2009-02-18 NZ NZ587350A patent/NZ587350A/en not_active IP Right Cessation
- 2009-02-18 BR BRPI0907826 patent/BRPI0907826A2/pt not_active IP Right Cessation
- 2009-02-18 EP EP09711989.5A patent/EP2245029B1/en active Active
- 2009-02-18 CA CA2715947A patent/CA2715947C/en not_active Expired - Fee Related
- 2009-02-18 PE PE2009000239A patent/PE20091473A1/es not_active Application Discontinuation
- 2009-02-19 CL CL2009000381A patent/CL2009000381A1/es unknown
- 2009-02-19 TW TW098105331A patent/TWI457338B/zh not_active IP Right Cessation
- 2009-02-19 JO JOP/2009/0075A patent/JO3014B1/ar active
- 2009-02-20 US US12/378,997 patent/US8049016B2/en not_active Expired - Fee Related
-
2010
- 2010-08-11 ZA ZA2010/05725A patent/ZA201005725B/en unknown
- 2010-08-12 CR CR11629A patent/CR11629A/es unknown
- 2010-08-12 IL IL207578A patent/IL207578A/en not_active IP Right Cessation
- 2010-08-19 HN HN2010001647A patent/HN2010001647A/es unknown
- 2010-08-19 CU CUP2010000170A patent/CU23890B1/es active IP Right Grant
- 2010-08-19 CO CO10102259A patent/CO6290655A2/es active IP Right Grant
- 2010-08-20 EC EC2010010411A patent/ECSP10010411A/es unknown
- 2010-08-20 SV SV2010003650A patent/SV2010003650A/es unknown
- 2010-09-09 MA MA33156A patent/MA32150B1/fr unknown
- 2010-12-02 HK HK10111248.5A patent/HK1144808A1/xx not_active IP Right Cessation
-
2011
- 2011-09-21 US US13/238,081 patent/US8318949B2/en not_active Expired - Fee Related
-
2014
- 2014-03-19 JP JP2014056951A patent/JP5813162B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070429A1 (es) | Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| AR061222A1 (es) | Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd. | |
| AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| AR046308A1 (es) | Derivados amida | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| AR127309A2 (es) | Derivados de piridazinona | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR074002A1 (es) | Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir) | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |